Analystreport

Stoke Therapeutics (NASDAQ: STOK) is now covered by analysts at Canaccord Genuity. They set a "buy" rating on the stock.

Stoke Therapeutics, Inc.  (STOK) 
Last stoke therapeutics, inc. earnings: 11/12 08:00 am Check Earnings Report